LP-10 (Oral Rinse)
Oral Lichen Planus (OLP)
Key Facts
About Lipella Pharmaceuticals
Lipella Pharmaceuticals is a clinical-stage biotech company with a mission to transform the treatment of mucosal diseases through its proprietary, localized liposomal delivery platform. The company has achieved key milestones including multiple FDA Orphan Drug Designations, positive Phase 2a data in hemorrhagic cystitis, and active Phase 2 trials in oral lichen planus and oral graft-versus-host disease. Its strategy leverages the 505(b)(2) regulatory pathway to repurpose proven drugs with novel delivery, aiming for faster, lower-risk development of therapies for areas of high unmet need.
View full company profileAbout Lipella Pharmaceuticals
Lipella Pharmaceuticals is a clinical-stage biotech company with a mission to transform the treatment of mucosal diseases through its proprietary, localized liposomal delivery platform. The company has achieved key milestones including multiple FDA Orphan Drug Designations, positive Phase 2a data in hemorrhagic cystitis, and active Phase 2 trials in oral lichen planus and oral graft-versus-host disease. Its strategy leverages the 505(b)(2) regulatory pathway to repurpose proven drugs with novel delivery, aiming for faster, lower-risk development of therapies for areas of high unmet need.
View full company profileTherapeutic Areas
Other Oral Lichen Planus (OLP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tregalizumab | CD4 Therapeutics | Phase 2 |